FDA approves Jemperli for biomarker-defined rectal cancer

The FDA granted accelerated approval to Jemperli for adults with stage II or III locally advanced rectal cancer that tests positive for microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR). The approval covers a biomarker-defined patient group, with an FDA-authorized test for solid tumors required to establish eligibility.

Jemperli is the brand name for dostarlimab-gxly. The decision rests on AZUR-1, a phase 2 study of previously untreated patients. The study enrolled 154 people and used a single-arm, open-label design, according to the trial details reported by EMPR. The sources describe the treatment as dostarlimab; OncLive says AZUR-1 evaluated the drug alone.

Among investigator-evaluable patients, the clinical complete response rate at 12 weeks was 68%, with a 95% confidence interval of 60% to 76%, OncLive reported. The same outlet gives an overall response rate of 82%, with a 95% confidence interval of 75% to 88%. These are trial results, not estimates that every patient meeting the biomarker criteria will have the same outcome.

The assessment schedule included evaluations at week six and week 12, plus another assessment about three weeks after treatment ended. Researchers used endoscopy, rectal MRI, and CT scans covering the chest, abdomen, and pelvis to assess responses, EMPR reported. The regulatory pathway is an important qualification.

PharmExec characterized the decision as conditional under accelerated approval and said independent-review data were still maturing. That account foregrounds the approval’s conditional status and the pending maturation of review data, while OncLive emphasizes the response figures among investigator-evaluable patients; the accounts do not report conflicting response estimates.

The approval makes Jemperli an approved immunotherapy option for this specific locally advanced rectal cancer subgroup, as also stated in headlines from Yahoo and GSK. The eligibility test and disease stage limit the indication: it applies to adults with stage II or III disease that is MSI-H or dMMR, rather than to rectal cancer generally.

The materials describe the FDA action and the AZUR-1 evidence supporting it, but do not provide a separate account of the FDA’s review criteria or a timetable for additional independent-review results. The practical next point is whether further review data develop and how clinicians apply the authorized testing requirement when considering this indication.